JNJ

226.17

-0.57%↓

UNH

367.12

-0.51%↓

TMO

467.38

-0.4%↓

ISRG

455.94

-0.36%↓

ABT

89.02

-0.55%↓

JNJ

226.17

-0.57%↓

UNH

367.12

-0.51%↓

TMO

467.38

-0.4%↓

ISRG

455.94

-0.36%↓

ABT

89.02

-0.55%↓

JNJ

226.17

-0.57%↓

UNH

367.12

-0.51%↓

TMO

467.38

-0.4%↓

ISRG

455.94

-0.36%↓

ABT

89.02

-0.55%↓

JNJ

226.17

-0.57%↓

UNH

367.12

-0.51%↓

TMO

467.38

-0.4%↓

ISRG

455.94

-0.36%↓

ABT

89.02

-0.55%↓

JNJ

226.17

-0.57%↓

UNH

367.12

-0.51%↓

TMO

467.38

-0.4%↓

ISRG

455.94

-0.36%↓

ABT

89.02

-0.55%↓

Search

CareDx Inc

Open

SectorGezondheidszorg

21.51 3.51

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

21.39

Max

21.98

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.8M

-4.1M

Verkoop

8.3M

108M

K/W

Sectorgemiddelde

14.645

67.147

EPS

0.12

Winstmarge

-3.79

Werknemers

761

EBITDA

-5.7M

1.5M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+15.02% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

119M

1.1B

Vorige openingsprijs

18

Vorige sluitingsprijs

21.51

Nieuwssentiment

By Acuity

40%

60%

112 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 mei 2026, 23:47 UTC

Winsten

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 mei 2026, 22:35 UTC

Winsten

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 mei 2026, 23:39 UTC

Marktinformatie

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 mei 2026, 23:34 UTC

Marktinformatie

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 mei 2026, 23:32 UTC

Winsten

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 mei 2026, 23:30 UTC

Marktinformatie

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 mei 2026, 23:20 UTC

Marktinformatie

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 mei 2026, 23:16 UTC

Acquisities, Fusies, Overnames

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 mei 2026, 22:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 mei 2026, 22:45 UTC

Marktinformatie

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 mei 2026, 22:20 UTC

Winsten

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 mei 2026, 22:08 UTC

Winsten

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 mei 2026, 22:05 UTC

Winsten

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 mei 2026, 22:05 UTC

Winsten

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 mei 2026, 22:05 UTC

Winsten

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 mei 2026, 22:04 UTC

Winsten

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 mei 2026, 22:03 UTC

Winsten

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 mei 2026, 22:03 UTC

Winsten

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 mei 2026, 22:02 UTC

Winsten

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 mei 2026, 22:02 UTC

Winsten

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 mei 2026, 22:02 UTC

Winsten

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 mei 2026, 22:01 UTC

Winsten

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 mei 2026, 22:01 UTC

Winsten

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 mei 2026, 22:01 UTC

Winsten

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 mei 2026, 15:06 UTC

Winsten

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

15.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 24.73 USD  15.02%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

112 / 347 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat